unknown
Stage
1992
Founded
2
Investors
About
Bluebird Bio, now rebranded as Genetix Biotherapeutics, develops and commercializes genetic therapies based on gene-modified autologous blood stem cells to treat rare genetic diseases such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
Explore Bluebird Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.